BRIEF-Rallybio Announces Initiation Of Dosing In RLYB212 Phase 2 Clinical Trial

Reuters
11 Feb
BRIEF-Rallybio Announces Initiation Of Dosing In RLYB212 Phase 2 Clinical Trial

Feb 11 (Reuters) - Rallybio RLYB.O:

  • RALLYBIO ANNOUNCES INITIATION OF DOSING IN RLYB212 PHASE 2 CLINICAL TRIAL

  • RALLYBIO CORP - PK AND SAFETY DATA EXPECTED IN 2Q AND 3Q 2025

Source text: ID:nBw34KkMla

Further company coverage: RLYB.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10